This underscores the importance of further studies to delineate precise and novel immunotherapy of COAD better and help explain the underlying COAD’s molecular mechanism modifications, guiding the clinical doctors to treat the immunotherapy that targets the EGFP and PD-1 carefully. This evidence concerns the gene PDCD1 and colon adenocarcinoma.